Mosby's 2014 Nursing Drug Reference (42 page)

BOOK: Mosby's 2014 Nursing Drug Reference
3.95Mb size Format: txt, pdf, ePub
ads
Do not confuse:

argatroban
/Aggrastat

ACTION:

Direct inhibitor of thrombin, it reversibly binds to thrombin active site

USES:

Anticoagulation prevention/treatment of thrombosis in heparin-induced thrombocytopenia; adjunct to percutaneous coronary intervention (PCI) in those with history of HIT

Unlabeled uses:
Acute MI, DIC, use in infants/children/adolescents

CONTRAINDICATIONS:

Hypersensitivity, overt major bleeding

Precautions:
Pregnancy (B), breastfeeding, children, intracranial bleeding, renal function impairment, hepatic disease, severe hypertension, after lumbar puncture, spinal anesthesia, major surgery, congenital/acquired bleeding, GI ulcers

DOSAGE AND ROUTES
Calculator
DVT, Pulmonary Embolism

• Adult: CONT IV INF
2 mcg/kg/min; adjust dose until steady-state aPTT is 1.5-
3× initial baseline, max 100 sec, max dose 10 mcg/kg/min

• Infant/child/adolescent (unlabeled):
CONT IV INF
0.75 mcg/kg/min, monitor aPTT q2hr until stable then at least daily

Hepatic dose

• Adult: CONT INF
0.5 mcg/kg/min, adjust rate based on aPTT

Percutaneous coronary intervention (PCI) in HIT

• Adult: IV INF
25 mcg/kg/min and bolus of 350 mcg/kg given over 3-5 min, check ACT 5-10 min after bolus completed, proceed if ACT >300 sec; if ACT <300 sec, give another 150 mcg/kg
BOL,
increase inf rate to 30 mcg/kg/min, recheck ACT in 5-10 min; if ACT >450 sec, decrease inf rate to 15 mcg/kg/min, recheck ACT in 5-10 min; when ACT is therapeutic, continue for duration of procedure

Acute MI (unlabeled)

• Adult: IV
loading dose of 1000 mcg/kg over 1 min, then 1-3 mcg/kg/min

DIC (unlabeled)

• Adult: CONT IV
0.7 mcg/kg/min

Available forms:

Inj 100 mg/ml (2.5 ml; must dilute 100-fold)

Administer:

• 
Avoid all IM inj that may cause bleeding

IV, direct route

• 
For PCI:
350 mg/kg bol and continuous inf of 25 mcg/kg/min; check ACT 5-10 min after bolus

Intermittent IV INF route

• 
Dilute
in 0.9% NaCl, D
5
, LR to a final conc of 1 mg/ml;
dilute
each 2.5-ml vial 100-fold by mixing with 250 ml of diluent, mix by repeated inversion of the diluent bag for 1 min; may briefly be slightly hazy

• 
Dosage adjustment may be made after review of aPTT, max 10 mcg/kg/min

SIDE EFFECTS

CNS:
Fever
,
intracranial bleeding,
headache

CV:
Atrial fibrillation, coronary thrombosis, MI, myocardial ischemia, coronary occlusion, ventricular tachycardia, bradycardia,
chest pain, hypotension

GI:
Nausea, vomiting, abdominal pain, diarrhea
,
GI bleeding

GU:
Hematuria,
abnormal kidney function, UTI

HEMA:
Hemorrhage

MISC:
Back pain, headache
, infection

RESP:
Pneumonia, dyspnea, coughing, hemoptysis

SYST:
Sepsis

PHARMACOKINETICS

Metabolized in liver by P450 CYP3A 4/5, distributed to extracellular fluid, 54% plasma protein binding, half-life 39-51 min, excreted in feces, steady state 1-3 hr

INTERACTIONS

Increase:
bleeding risk—antiplatelets, NSAIDs, salicylates, dipyridamole, clopidogrel, ticlopidine, heparin, warfarin, glycoprotein IIb/IIIa antagonists (abciximab, tirofiban, eptifibatide), thrombolytics (alteplase, reteplase, urokinase, tenecteplase), other anticoagulants

NURSING CONSIDERATIONS
Assess:

• 
Baseline aPTT before treatment; do not start treatment if aPTT ratio is ≥2.5, then check aPTT 2 hr after initiation of treatment and at least daily thereafter

• 
aPTT, which should be 1.5-3 × control, draw blood for ACT every 20-30 min during long PCI

 
Bleeding
gums: petechiae; ecchymosis; black, tarry stools; hematuria/epistaxis; B/P; vaginal bleeding, possible hemorrhage

 
Anaphylaxis:
dyspnea, rash during treatment

• 
Fever, skin rash, urticaria

Evaluate:

• 
Therapeutic response: absence or decrease of thrombosis

Teach patient/family:

• 
To use a soft-bristle toothbrush to avoid bleeding gums; avoid contact sports; use electric razor; avoid IM inj

• 
To report any signs of bleeding: gums, under skin, urine, stools; trouble breathing wheezing, skin rash

• 
To notify prescriber if planning to become pregnant, breastfeeding

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

ARIPiprazole (Rx)

(a-rip-ip-pra′zol)

Abilify, Abilify Discmelt

Func. class.:
Antipsychotic

Chem. class.:
Quinolinone

ACTION:

Exact mechanism unknown; may be mediated through both DOPamine type 2 (D
2
, D
3
) and serotonin type 2 (5-HT
1A
, 5-HT
2A
) antagonism

USES:

Schizophrenia and bipolar disorder (adults and adolescents), agitation, mania, major depressive disorder, short-term mania or mixed episodes of bipolar disorder; irritability in patients with autism

Unlabeled uses:

Psychosis in patients with dementia

CONTRAINDICATIONS:

Breastfeeding, hypersensitivity, seizure disorders

Precautions:
Pregnancy (C), geriatric patients, renal/hepatic/cardiac disease

 

Black Box Warning:

Children, dementia, suicidal ideation

DOSAGE AND ROUTES
Calculator
Major depressive disorder

• Adult: PO
2-5 mg/day as an adjunct to other antidepressant treatment; adjust by 5 mg at ≥1 wk (range, 2-15 mg/day)

Schizophrenia

• Adult: PO
10-15 mg/day; if needed, dosage may be increased to 30 mg/day after 2 wk; maintenance 15 mg/day; periodically reassess

• Adolescent 13-17 yr: PO
2 mg/day, may increase to 5 mg after 2 days, then 10 mg after 2 more days, max 30 mg/day

Bipolar disorder

• Adult: PO
15 mg/day, may increase to 30 mg if needed (monotherapy); adjunctive to lithium or valproate PO 10-15 mg qd, may increase to 30 mg if needed

• Child >10 yr, adolescents: PO
2 mg, titrate to 5 mg/day after 2 days to target of 10 mg/day after another 2 days

Agitation with bipolar disorder/schizophrenia

• Adult: IM
9.75 mg as a single dose, may start with a lower dose, max 30 mg/day

Irritability associated with autism

• Child

6 yr, adolescents: PO
2 mg/day, increase to 5 mg/day after 1 wk, may increase to 10-15 mg/day if needed; dose changes should not occur more frequently than q1wk

Potential CYP2D6 inhibitor, strong CYP3A4 inhibitors

• Adult: PO
Reduce to 50% of usual dose, increase dose when CYP2D6, CYP3A4 inhibitor withdrawn

Combination of strong CYP3A4/CYP2D6 inhibitors

• Adult: PO
reduce to 25% of usual dose

Acute psychosis (unlabeled)

• Adults: PO
15 mg/day, may increase to 20-30 mg/day after 3 wk

Available forms:

Tabs 2, 5, 10, 15, 20, 30 mg; inj 9.75 mg/1.3 ml; orally disintegrating tab 10, 15 mg; oral sol 1 mg/ml

Administer:
PO route

• 
May be given without regard to meals

• 
Orally disintegrating tabs; do not open blister until ready to use, do not push tab through foil; place on tongue, allow to dissolve, swallow, do not divide

• 
Oral liquid: use calibrated measuring device

• 
Oral solution: can be substituted for tablet on a mg-per-mg, up to 25 mg dose. Patients receiving 30-mg tablets should receive 25 mg of solution

IM route

• 
Give IM only; inject slowly, deeply into muscle mass; discard unused portion

SIDE EFFECTS

CNS:
Drowsiness, insomnia, agitation, anxiety, headache
,
seizures, neuroleptic malignant syndrome,
light-headedness, akathisia, asthenia, tremor
,
stroke, suicidal ideation,
dystonia

CV:
Orthostatic hypotension,
tachycardia

EENT:
Blurred vision, rhinitis

GI:
Constipation, nausea, vomiting
, jaundice,
weight gain

BOOK: Mosby's 2014 Nursing Drug Reference
3.95Mb size Format: txt, pdf, ePub
ads

Other books

A Whisper of Desire by Bronwen Evans
The Gay Metropolis by Charles Kaiser
Craving Absolution by Nicole Jacquelyn
Cold Courage by Pekka Hiltunen
Lentil Underground by Liz Carlisle